Ambrx Biopharma Inc

Ambrx Biopharma Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ambrx Biopharma, Inc. is a clinical-stage biologics company, which engages in discovering and developing a novel class of engineered precision biologics (EPBs). Using its proprietary expanded genetic code technology platform, it allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, and ARX305. The company was founded on August 11, 2023 and is headquartered in La Jolla, CA.

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that Feng Tian, Ph.D., Chairman of the Board, President, and CEO of Ambrx, will participate in the Cowen 42nd Annual Health Care Conference taking place March 7-9, 2022. Dr. Tian is scheduled to participate in the ‘Breast Cancer' corporate panel discussion on Wednesday, Mar

Ambrx Biopharma Inc. to Participate in the Cowen 42nd Annual Health Care Conference

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced it received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) related to an Investigational New Drug (IND) application for ARX305, an antibody drug conjugate (ADC) designed to target CD70 to treat a broad range of solid and hematologic tumors suc

Ambrx Biopharma Inc. Announces Submission of IND Application for ARX305 with the U.S. FDA

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the appointment of Paul V. Maier to its Board of Directors and as Chair of the Audit Committee. “I am thrilled to welcome Paul to our Board and look forward to having him serve as the Chair of our Audit Committee moving forward,” said Feng Tian, Ph.D., Chairman of the Boar

Ambrx Biopharma Inc. Appoints Paul Maier to Board of Directors and as Chair of the Audit Committee

Ambrx Biopharma (AMAM) has been struggling lately, but the selling pressure may be coming to an end soon.

Ambrx Biopharma (AMAM) Sees Hammer Chart Pattern: Time to Buy?

The stock price of Ambrx Biopharma Inc (NYSE: AMAM) increased by over 29% during intraday trading today. This is why it happened.

Ambrx Biopharma Stock (AMAM): Why The Price Jumped Today

Ambrx Biopharma Inc's (NYSE: AMAM) partner in China, NovoCodex Pharmaceuticals Ltd, presented favorable safety and efficacy data from its ongoing ACE-Breast-01 Phase 1 study of ARX788 at the San Antonio Breast Cancer Symposium (SABCS). ARX788 demonstrated treatment effect among patients who previously failed a median of seven anti-HER2 targeting therapies.

Ambrx Biopharma Shares Jump After Safety, Efficacy Data From Breast Cancer Trial

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc. Presents Positive Data from Ongoing ACE-Breast-01 Phase 1 Clinical Study of ARX788 at San Antonio Breast Cancer Symposium

Ambrx Biopharma Inc. Presents Positive Data from Ongoing ACE-Breast-01 Phase 1 Clinical Study of ARX788 at San Antonio Breast Cancer Symposium

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium

Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium

SAN DIEGO--(BUSINESS WIRE)--Ambrx Announces First Patient Dosed in Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for Treatment of HER2-Positive Metastatic Breast Cancer

Ambrx Biopharma Inc. Announces First Patient Dosed in its Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for the Treatment of HER2-Positive Metastatic Breast Cancer

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference

Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc. Reports 1H 2021 Financial Results and Provides Corporate Update

Ambrx Biopharma Inc. Reports 1H 2021 Financial Results and Provides Corporate Update

SAN DIEGO--(BUSINESS WIRE)--Ambrx Announces Positive Data on ARX788 for the treatment of HER2+ Gastric Cancer Presented at CSCO

Ambrx Announces Positive Data on ARX788 for the Treatment of HER2+ Gastric Cancer Presented at CSCO

SAN DIEGO--(BUSINESS WIRE)--Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference

Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO--(BUSINESS WIRE)--Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors

Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors

SAN DIEGO--(BUSINESS WIRE)--Ambrx Appoints Sonja Nelson as Chief Financial Officer

Ambrx Appoints Sonja Nelson as Chief Financial Officer

Atai Life Sciences BV

Cyteir Therapeutics

Codex DNA

Femasys

Century Therapeutics

Going public on Friday: atai Life Sciences, Ambrx Biopharma, Century Therapeutics, Codex DNA, Cyteir Therapeutics, and Femasys.

Peter Thiel's Atai Life Sciences and 5 Other Companies List Shares

SAN DIEGO--(BUSINESS WIRE)--Ambrx Announces Pricing of Initial Public Offering

News for Ambrx Biopharma Inc Stock (AMAM)